Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Antitumor activity observed with confirmed partial responses in 50% of patients
at highest dose tested to date, across multiple tumor types

PLN-101095 was generally well tolerated across all doses

Read more at globenewswire.com